| 2026-02-10 |
详情>>
股本变动：
变动后总股本6335.88万股
变动原因 ▼▲
- 原因：
- From December 31, 2024 to December 31, 2025
Repurchase of ordinary shares
Exercise of options and vesting of RSUs
|
| 2026-02-10 |
详情>>
业绩披露：
2025年年报每股收益1.45美元,归母净利润9383.10万美元,同比去年增长-48.24%
|
| 2026-02-10 |
财报披露：
美东时间 2026-02-10 盘前发布财报
|
| 2025-11-05 |
详情>>
业绩披露：
2025年三季报(累计)每股收益1.03美元,归母净利润6680.60万美元,同比去年增长-32.18%
|
| 2025-07-30 |
详情>>
业绩披露：
2025年中报每股收益0.68美元,归母净利润4494.30万美元,同比去年增长-5.41%
|
| 2025-04-28 |
详情>>
业绩披露：
2025年一季报每股收益0.26美元,归母净利润1820.10万美元,同比去年增长-23.19%
|
| 2025-04-03 |
股东大会：
将于2025-05-15召开股东大会
会议内容 ▼▲
- 1.To re-elect each of Mr. Moshe Mizrahy and Dr. Michael Kreindel, to the Company’s Board, to serve as a Class III directors of the Company, and to hold office until the close of business on the date of the Company’s annual general meeting of shareholders to be held in 2028 and until such individual’s successor is duly elected and qualified, or until such individual’s earlier resignation or retirement;
2.To approve the re-appointment of Kesselman & Kesselman, Certified Public Accountants (Isr.), a member of PricewaterhouseCoopers International Limited (“PwC”), our independent registered public accounting firm, as the Company’s independent auditors for the fiscal year ending December 31, 2025, and its service until the annual general meeting of shareholders to be held in 2026;
3.To approve the grant of a total of 7,000 restricted share units (“RSUs”) under the Company’s 2018 Incentive Plan to each of our following directors: Dr. Hadar Ron (2,000 RSUs), Dr. Michael Anghel (2,000 RSUs) and Mr. Nadav Kenneth (3,000 RSUs), half of which shall vest on February 15, 2026, and the remaining half of which shall vest on February 15, 2027, subject to their continued service on the date of vesting.
|
| 2025-02-04 |
详情>>
业绩披露：
2022年年报每股收益1.96美元,归母净利润1.62亿美元,同比去年增长-2.09%
|
| 2025-02-04 |
详情>>
业绩披露：
2024年年报每股收益2.29美元,归母净利润1.81亿美元,同比去年增长-8.41%
|
| 2024-10-30 |
详情>>
业绩披露：
2024年三季报(累计)每股收益1.20美元,归母净利润9850.40万美元,同比去年增长-31%
|
| 2024-08-01 |
详情>>
业绩披露：
2024年中报每股收益0.56美元,归母净利润4751.40万美元,同比去年增长-50.63%
|
| 2024-05-02 |
详情>>
业绩披露：
2024年一季报每股收益0.28美元,归母净利润2369.60万美元,同比去年增长-41.5%
|
| 2024-02-13 |
股东大会：
将于2024-04-01召开股东大会
会议内容 ▼▲
- 1.To re-elect Dr. Michael Anghel (who is an incumbent director), and to elect Mr. Nadav Kenneth (as a new director, replacing Mr. Bruce Mann who is retiring), to the Company's board of directors, both to serve as a Class II directors of the Company, and to hold office until the close of business of the annual general meeting of shareholders to be held in 2027 and until such individual's successor is duly elected and qualified, or until such individual's earlier resignation or retirement;
2.To approve the renewal for an additional three-year period of an updated version of the compensation policy for the executive officers and directors of the Company, or the Compensation Policy, in accordance with the requirements of the Israeli Companies Law;
3.To authorize our currently serving chief executive officer and chairman of the board of directors, Mr. Moshe Mizrahy, to continue serving as both our chief executive officer and chairman of our board of directors, for an additional period of up to three years from the date of the Meeting, in accordance with the requirements of the Israeli Companies Law;
4.To approve the re-appointment of Kesselman & Kesselman Certified Public Accounts, a member of PwC, as the Company’s independent auditors for the fiscal year ending December 31, 2024, and its service until the annual general meeting of shareholders to be held in 2025;
5.To approve the grant to each of our following directors: Dr. Hadar Ron and Dr. Michael Anghel, of 2,000 restricted share units under the Company's 2018 Incentive Plan totaling 4,000 restricted share units, half of which shall vest on February 12, 2025, and the remaining half shall vest on February 12, 2026;
6.To approve the acceleration of unvested RSUs previously granted to our currently serving Director, Mr. Bruce Mann, which remain unvested upon expiration of his term of office at the Meeting.
|
| 2024-02-13 |
详情>>
业绩披露：
2023年年报每股收益2.37美元,归母净利润1.98亿美元,同比去年增长22.54%
|
| 2023-02-14 |
股东大会：
将于2023-04-03召开股东大会
会议内容 ▼▲
- 1.To re-elect Dr. Hadar Ron to serve as a Class I director of the Company, and to hold office until the close of business of the annual general meeting of shareholders to be held in 2026 and until her respective successor is duly elected and qualified, or until her earlier resignation or retirement.
2.To approve an increase in the number of the Company's authorized ordinary shares and authorized share capital, and to amend and restate the Articles of Association of the Company to reflect such increase.
3.To approve an amendment to the terms of engagement of the Company's Chief Executive Officer and Chairman of the Board, Mr. Moshe Mizrahy.
4.To approve an amendment to the terms of engagement of the Company's Chief Technology Officer (and a member of the Board), Dr. Michael Kreindel.
5.To approve the grant to each of our following non-executive directors: Dr. Michael Anghel, Mr. Bruce Mann and Dr. Hadar Ron, of 2,000 restricted share units under the Company's 2018 Incentive Plan totaling 6,000 restricted share units, half of which shall vest on February 13, 2024, and the remaining half shall vest on February 13, 2025.
6.To approve the re-appointment of Kesselman & Kesselman Certified Public Accounts, a member of PwC, as the Company’s independent auditors for the fiscal year ending December 31, 2023, and its service until the annual general meeting of shareholders to be held in 2024.
|
| 2022-02-10 |
股东大会：
将于2022-04-04召开股东大会
会议内容 ▼▲
- 1.to re-elect each of Mr. Moshe Mizrahy and Dr. Michael Kreindel to serve as a Class III director of the Company, and to hold office until the close of business of the annual general meeting of shareholders to be held in 2025 and until their respective successors are duly elected and qualified, or until such individual's earlier resignation or retirement;
2.to approve an increase in the number of the Company's authorized ordinary shares and authorized share capital, and to amend and restate the Articles of Association of the Company to reflect such increase.
3.to approve the re-appointment of Kesselman & Kesselman Certified Public Accounts, a member of PwC, as the Company’s independent auditors for the fiscal year ending December 31, 2022, and its service until the annual general meeting of shareholders to be held in 2023.
4.to approve the grant to each of our following directors: Dr. Michael Anghel, Mr. Bruce Mann and Dr. Hadar Ron, of 2,000 restricted share units under the Company's 2018 Incentive Plan totaling 6,000 restricted share units, half of which shall vest on December 31, 2022, and the remaining half shall vest on December 31, 2023.
|
| 2021-10-01 |
详情>>
拆分方案：
每1.0000股拆分成2.0000股
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-02-10 |
股东大会：
将于2021-04-05召开股东大会
会议内容 ▼▲
- 1.to re-elect each of Dr. Michael Anghel and Mr. Bruce Mann to serve as a Class II director of the Company, and to hold office until the close of business of the annual general meeting of shareholders to be held in 2024 and until his successor is duly elected and qualified, or until such individual's earlier resignation or retirement;
2.to approve the re-appointment of Kesselman & Kesselman Certified Public Accounts, a member of PwC, as the Company’s independent auditors for the fiscal year ending December 31, 2021, and its service until the annual general meeting of shareholders to be held in 2022.
3.to approve the grant to each of our following directors: Dr. Michael Anghel, Mr. Bruce Mann and Dr. Hadar Ron, of 1,000 restricted share units under the Company's 2018 Incentive Plan totaling 3,000 restricted share units, half of which shall vest on December 31, 2021 and the remaining half shall vest on December 31, 2022.
|
| 2020-05-11 |
股东大会：
将于2020-06-16召开股东大会
会议内容 ▼▲
- 1.to ratify and approve the re-pricing of certain options previously granted by the Company on November 25, 2019, January 7, 2020, January 28, 2020 and February 17, 2020 to U.S. participants (except for such grants to Executive Officers as set out in Proposals 2, 3 and 4 below), by way of cancellation and re-grant of such options under the same terms and conditions as originally granted (including the same vesting schedule) but with a lower exercise price, as previously approved by the Company's Compensation Committee and Board on March 15, 2020.
2.to ratify and approve the re-pricing of certain options previously granted on January 7, 2020 by the Company's Compensation Committee and Board, to the Company's Executive Officer, Mr. Shakil Lakhani (President – North America), by way of cancellation and re-grant of such options under the same terms as originally granted (which terms exceeds the limits set forth in the Company's Compensation Policy which was in effect at the time of such re-grant) but with a lower exercise price, as previously approved by the Company's Compensation Committee and Board on March 15, 2020.
3.to ratify and approve the re-pricing of certain options previously granted on January 7, 2020 by the Company's Compensation Committee and Board, to the Company's Executive Officer, Mr. Yair Malca (Chief Financial Officer), by way of cancellation and re-grant of such options under the same terms as originally granted (which terms exceeds the limits set forth in the Company's Compensation Policy which was in effect at the time of such re-grant) but with a lower exercise price, as previously approved by the Company's Compensation Committee and Board on March 15, 2020.
4.to ratify and approve the re-pricing of certain options previously granted on January 7, 2020 by the Company's Compensation Committee and Board, to the Company's Executive Officer, Dr. Spero Theodorou (Chief Medical Officer), by way of cancellation and re-grant of such options under the same terms as originally granted (which terms exceeds the limits set forth in the Company's Compensation Policy which was in effect at the time of such re-grant) but with a lower exercise price, as previously approved by the Company's Compensation Committee and Board on March 15, 2020.
|
| 2020-02-18 |
股东大会：
将于2020-04-02召开股东大会
会议内容 ▼▲
- 1.to re-elect Dr. Hadar Ron to serve as a Class I director of the Company, and to hold office until the close of business of the annual general meeting of shareholders to be held in 2023 and until her successor is duly elected and qualified, or until such individual’s earlier resignation or retirement;
2.to approve an amended and restated compensation policy for executive officers and directors in accordance with the provisions of the Israeli Companies Law 5759-1999;
3.to ratify and approve the grant of options previously approved on January 7, 2020 by the compensation committee and the Board, to the Company's executive officer, Mr. Shakil Lakhani (President – North America), upon terms which exceed the limits set forth in the Compensation Policy which was in effect at the time of grant;
4.to ratify and approve the grant of options previously approved on January 7, 2020 by the compensation committee and the Board, to the Company's executive officer, Mr. Yair Malca (Chief Financial Officer), upon terms which exceed the limits set forth in the Compensation Policy which was in effect at the time of grant;
5.to ratify and approve the grant of options previously approved on January 7, 2020 by the compensation committee and the Board, to the Company's executive officer, Dr. Spero Theodorou (Chief Medical Officer), upon terms which exceed the limits set forth in the Compensation Policy which was in effect at the time of grant;
6.to ratify and approve an update to the engagement terms of Mr. Shakil Lakhani, President – North America, previously approved by the compensation committee and the Board, upon terms which exceed the limit set forth in the Compensation Policy which was in effect at the time of approval;
7.to approve the reappointment of Kesselman & Kesselman Certified Public Accounts, a member of PwC, as the Company’s independent auditors for the fiscal year ending December 31, 2020, and its service until the annual general meeting of shareholders to be held in 2021.
|
| 2011-01-03 |
详情>>
内部人交易：
CANET GERARDO等共交易18笔
|